A role for GM-CSF DNA as an adjuvant was established in a phase I/II trial using a DNA vaccine encoding for hgp100 and tyrosinase epitopes resulting in specific CD8+ responses in 42% of the treated melanoma patients [95]. The gene discussed is CD8A; the disease is melanoma.